Category: Blog

The pharmaceutical landscape is shifting. It’s no longer just about developing groundbreaking therapies; it’s about ensuring those therapies reach the right patients, at the right time, and that those patients are empowered throughout their journey. Traditional methods of patient recruitment and engagement – relying heavily on clinician referrals and broad-stroke awareness campaigns – are often…

In today’s increasingly complex pharmaceutical landscape, companies are constantly seeking ways to optimize their market presence and maintain competitive pricing. One often overlooked opportunity in the European Union is parallel importing – a legitimate practice that can offer significant benefits to various stakeholders in the pharmaceutical supply chain. What is Parallel Importing? Parallel importing in…

France is home to one of Europe’s most dynamic pharmaceutical and biotechnology ecosystems, making it a prime location for Contract Research Organizations (CROs). With a robust infrastructure, a commitment to innovation, and a strong regulatory framework, France has emerged as a strategic choice for companies seeking comprehensive research support. Below, we delve into what makes…

Expanding into Europe is a milestone for many pharmaceutical companies, offering access to one of the world’s largest healthcare markets. However, Europe is not a single, homogenous entity—it’s a patchwork of countries, each with unique regulatory requirements, pricing strategies, and market opportunities. A well-planned, localized approach is critical to succeed. Here’s a breakdown of some…

In the competitive world of prescription-only medicine (POM), brand positioning is crucial. It’s not just about having an effective treatment—it’s about ensuring your product stands out to healthcare professionals (HCPs), patients, and stakeholders. At Elliogen, we specialize in helping pharmaceutical companies develop tailored brand strategies that resonate and drive success. Why Brand Positioning Matters Trust…

Navigating the complexities of the French pharmaceutical market can be daunting for U.S. companies aiming to expand their operations internationally. This is particularly true given the stringent regulatory, safety, and quality standards that France enforces. Understanding the role and advantages of an ‘Exploitant’—a mandatory local representative for pharmaceutical companies—is crucial for any U.S. entity looking…

Introducing a pharmaceutical product into the European Union (EU) necessitates a thorough understanding of the regulatory pathways for obtaining marketing authorization. This is a critical step for pharmaceutical companies aiming to successfully navigate the complex regulatory framework of the EU. There are two principal pathways to consider: the Centralised Procedure (CP) and the Decentralised Procedure…

Early Access Programs (EAPs) are a crucial aspect of the pharmaceutical landscape, providing a pathway for patients with serious or life-threatening conditions to access investigational drugs prior to official approval. For pharmaceutical companies, understanding and effectively managing EAPs can be a game-changer. This blog post will delve into what EAPs entail and how pharmaceutical companies…

The French healthcare system offers a unique framework for prescription drugs, impacting pharmaceutical companies, prescribers, and patients alike. As a pharmaceutical company looking to operate in France, it’s crucial to understand the dynamics between branded and generic medicines, patient preferences, and the implications of the ‘non substitutable’ rule. This understanding is key to developing effective…